Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine

Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine

The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA) in patients with COVID-19 is analyzed in the article. There is controversy over the hypothesis that these drugs can be factors contributing to an unfavorable...

Full description

Bibliographic Details
Main Author:	S. Yu. Martsevich
Format:	Article
Language:	English
Published:	Столичная издательская компания 2020-05-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	covid-19 angiotensin converting enzyme inhibitors angiotensin receptor antagonists
Online Access:	https://www.rpcardio.online/jour/article/view/2165

Similar Items

Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera
by: Angela Bozza, et al.
Published: (2023-12-01)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
by: Si-Hyuck Kang, et al.
Published: (2021-06-01)

Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Mortality in Patients with Hypertension Hospitalized with COVID-19
by: Amirhossein Abedtash, et al.
Published: (2021-07-01)

Effect of renin-angiotensin system inhibitors on survival rate of patients with breast cancer: systematic review and meta-analysis
by: Niloufar Naghibzadeh, et al.
Published: (2020-08-01)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
by: Hyun Woo Lee, et al.
Published: (2021-03-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
by: Philip Braude, et al.
Published: (2020-12-01)

New Users of Angiotensin II Receptor Blocker–Versus Angiotensin‐Converting Enzyme Inhibitor–Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD‐BP and SPRINT
by: Jordan B. King, et al.
Published: (2023-09-01)

بررسی تأثیر ترکیب مهار کننده‌های آنزیم مبدل آنژیوتانسین و بلوک کننده‌های گیرنده‌ی آنژیوتانسین بر پیشرفت بیماری کلیوی در بیماران مبتلا به دیابت نوع 2 در مقایسه با تجویز هر یک از این دو دارو به تنهایی
by: Houshang Sanadgol, et al.
Published: (2016-04-01)

Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension
by: Jinwoo Lee, et al.
Published: (2021-03-01)

2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
by: Luigi Cappannoli, et al.
Published: (2020-12-01)

Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19
by: O. M. Drapkina, et al.
Published: (2020-07-01)

The problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experience
by: S R Gilyarevsky
Published: (2014-06-01)

Long-term oral ACEI/ARB therapy is associated with disease severity in elderly COVID-19 omicron BA.2 patients with hypertension
by: Zhe Zhang, et al.
Published: (2023-12-01)

Effects of RAS inhibitors on all-site cancers and mortality in the Hong Kong diabetes surveillance database (2002-2019)
by: Aimin Yang, et al.
Published: (2022-09-01)

Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia
by: Hae-Young Lee, et al.
Published: (2021-05-01)

Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study
by: Jae Hyun Bae, et al.
Published: (2021-05-01)

No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort
by: Gian Paolo Anzola, et al.
Published: (2020-09-01)

Post-induction hypotension with remimazolam versus propofol in patients routinely administered angiotensin axis blockades: a randomized control trial
by: Seung Woo Song, et al.
Published: (2023-06-01)

Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort studyResearch in context
by: Aimin Yang, et al.
Published: (2023-01-01)

Renin-angiotensin and kallikrein-kinin systems in diabetic renal damage
by: Igić Rajko
Published: (2019-01-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

Angiotensin converting enzyme inhibitors /
by: DeBrue, Anne N.
Published: (c200)

The use of angiotensin-converting enzyme inhibitors in general medicine
by: M.L.I. Mashitisho
Published: (2012-08-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome: A Retrospective Case Control Study
by: Joohae Kim, et al.
Published: (2017-05-01)

Angiotensin II and COVID-19. Secrets of interactions
by: A. O. Konradi, et al.
Published: (2020-05-01)

Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network
by: Steven M. Smith, et al.
Published: (2023-01-01)

Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs
by: Janina Hahn, et al.
Published: (2023-09-01)

Efficacy of different combinations of antihypertensive drugs in patients with nocturnal hypertension
by: LING Sha, TAN Bifeng， FU Wenzhe， CHENG Yuhua, ZHANG Xuan, LEI Jianming, ZENG Wangwei, PENG Zhiping, DING Shasha
Published: (2024-01-01)

Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication
by: Jae Hoon Kim, et al.
Published: (2017-03-01)

Antecedent Administration of Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID‐19 Syndrome
by: Alberto Palazzuoli, et al.
Published: (2020-11-01)

The effectiveness of zofenopril in patients with cardiovascular disease
by: V G Kukes, et al.
Published: (2014-06-01)

Angiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answer
by: S R Gilyarevsky, et al.
Published: (2013-03-01)

The effect of renin-angiotensin system blockers on aldosterone levels in patients with chronic heart failure with preserved ejection fraction
by: A. N. Shevelok
Published: (2020-12-01)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01)

A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01)

Effectiveness of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers on total and cardiovascular mortality and morbidity in primary prevention: A nationwide study based on French Health Insurance Data (SNDS)
by: Emmanuel Oger, et al.
Published: (2022-04-01)

THE INFLUENCE OF TISSUE ANGIOTENSINS ON ELEMENTS OF THE CARDIOVASCULAR SYSTEM (LECTURE)
by: Liudmila O Gutsol, et al.
Published: (2024-06-01)